
“Pharma Bro” Martin Shkreli filed motions in May to dismiss the Federal Trade Commission’s (FTC) claims that his company Vyera Pharmaceuticals boxed out competition and created a monopoly for the toxoplasmosis drug Daraprim after raising prices by 4,000% overnight. But on Tuesday, August 18, a federal judge said not so fast.
Judge Denise Cote denied all but one request for dismissal. The suit was filed in January by the Federal Trade Commission, New York, and other states, which claimed that Shkreli and co-defendant Kevin Mulleady participated in “an unlawful scheme” to hinder generic competition and “preserve a monopoly,” which they allegedly kept going even while Shkreli was in prison, according to court documents.
Shkreli and Mulleady launched Vyera in 2014, then known as Turing Pharmaceuticals, and snagged US rights to Daraprim for US$55 million the following year. Overnight, the company raised Daraprim’s price from US$17.50 to US$750 per tablet. The move was a familiar one for Shkreli, whose company Retrophin acquired the rights to Thiola in 2014, then raised its price by 2,000%, according to the FTC complaint.
Full Content: ENDPOINTS News
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
On Witness Stand, Google CEO Challenges DOJ’s Proposed Remedies In Search Monopoly Case
Apr 30, 2025 by
CPI
Latham & Watkins Expands German Antitrust Practice
Apr 30, 2025 by
CPI
DoorDash, Grubhub, and Uber Eats Settle With NYC Over Cap Fees
Apr 30, 2025 by
CPI
Pork Giants Push to Overturn Price-Fixing Suit Citing Clerk’s Alleged Conflicts
Apr 30, 2025 by
CPI
Novartis to Acquire Regulus Therapeutics in $1.7 Billion Deal
Apr 30, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Mergers in Digital Markets
Apr 21, 2025 by
CPI
Catching a Killer? Six “Genetic Markers” to Assess Nascent Competitor Acquisitions
Apr 21, 2025 by
John Taladay & Christine Ryu-Naya
Digital Decoded: Is There More Scope for Digital Mergers In 2025?
Apr 21, 2025 by
Colin Raftery, Michele Davis, Sarah Jensen & Martin Dickson
AI In the Mix – An Ever-Evolving Approach to Jurisdiction Over Digital Mergers in Europe
Apr 21, 2025 by
Ingrid Vandenborre & Ketevan Zukakishvili
Antitrust Enforcement Errors Due to a Failure to Understand Organizational Capabilities and Dynamic Competition
Apr 21, 2025 by
Magdalena Kuyterink & David J. Teece